{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:05:30Z","timestamp":1785168330206,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhep.2022.12.007","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:51:38Z","timestamp":1671825098000},"page":"534-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis"],"prefix":"10.1016","volume":"78","author":[{"given":"Won-Mook","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Brooks-Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Cant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Joo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neung Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Phil","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Woo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hsu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2022.12.007_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"10.1016\/j.jhep.2022.12.007_bib2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.jhep.2022.12.007_bib3","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis","volume":"14","author":"Gomaa","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.12.007_bib4","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jhep.2022.12.007_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.12.007_bib6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.12.007_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jhep.2019.06.013","article-title":"Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: one direction or no direction","volume":"71","author":"Choi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamaoncol.2018.4039","article-title":"Tenofovir vs. Entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B: one of these things is not like the other","volume":"5","author":"Flemming","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2022.12.007_bib9","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1111\/hepr.12743","article-title":"Efficacy and safety of entecavir vs. tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon","year":"2017","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials","volume":"98","author":"Cai","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir vs. entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.jhep.2022.12.007_bib12","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs. Tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"11","author":"Cheung","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2022.12.007_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","author":"Choi","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.12.007_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"issue":"12","key":"10.1016\/j.jhep.2022.12.007_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir vs. entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2022.12.007_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","article-title":"Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments","volume":"76","author":"Choi","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.12.007_bib19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir","volume":"66","author":"Shin","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.jhep.2022.12.007_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/sjg.SJG_49_18","article-title":"Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-na\u00efve and experienced patients with chronic hepatitis B","volume":"24","author":"Kim","year":"2018","journal-title":"Saudi J Gastroenterol"},{"issue":"12","key":"10.1016\/j.jhep.2022.12.007_bib21","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs. Tenofovir","volume":"18","author":"Oh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2022.12.007_bib22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.13194","article-title":"Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir\/tenofovir in South Korea","volume":"48","author":"Yu","year":"2018","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs. Tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2022.12.007_bib24","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jgh.15031","article-title":"Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis","volume":"35","author":"Ha","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","article-title":"Long-term risk of primary liver cancers in entecavir vs. tenofovir treatment for chronic hepatitis B","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jhep.2022.12.007_bib26","first-page":"3882","article-title":"Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study","volume":"10","author":"Chen","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jhep.2022.12.007_bib27","doi-asserted-by":"crossref","first-page":"S887","DOI":"10.1016\/S0168-8278(20)32211-X","article-title":"Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan","volume":"73","author":"Huang","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.12.007_bib28","first-page":"S578A","article-title":"Occurrence of hepatocellular carcinoma in chronic hepatitis b patients undergoing entecavir or tenofovir treatment","volume":"70","author":"Lee","year":"2020","journal-title":"AASLD"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.12.007_bib30","series-title":"Micemd: multiple imputation by chained equations with multilevel data","author":"Audigier","year":"2019"},{"key":"10.1016\/j.jhep.2022.12.007_bib31","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.jhep.2022.12.007_bib32","series-title":"Random and mixed effects. Modern Applied Statistics with S","first-page":"271","author":"Venables","year":"2002"},{"issue":"9","key":"10.1016\/j.jhep.2022.12.007_bib33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir vs. entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"35","author":"Gu","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF vs. ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jhep.2022.12.007_bib35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jgh.15783","article-title":"Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis","volume":"37","author":"Yuan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2022.12.007_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjmed.2008.03.005","article-title":"Racial and ethnic variations in hepatocellular carcinoma incidence within the United States","volume":"121","author":"Wong","year":"2008","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jhep.2022.12.007_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10,397 individual participants","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2022.12.007_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs. Entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jhep.2022.12.007_bib40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","volume":"71","author":"P\u00e9neau","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2022.12.007_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/apt.12629","article-title":"Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA","volume":"39","author":"Gao","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients","volume":"48","author":"Koike","year":"2018","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Syst Rev"},{"issue":"1","key":"10.1016\/j.jhep.2022.12.007_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12876-017-0596-7","article-title":"Comparison of the long-term efficacy between entecavir and tenofovir in treatment- na\u00efve chronic hepatitis B patients","volume":"17","author":"Park","year":"2017","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2022.12.007_bib45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.jhep.2022.12.007_bib46","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-\u03bb in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2022.12.007_bib47","article-title":"Differential relapse patterns after discontinuation of entecavir vs. Tenofovir disoproxil fumarate in chronic hepatitis B","author":"Choi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.12.007_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/cancers12030641","article-title":"Inflammatory mechanisms of HCC development","volume":"12","author":"Refolo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jhep.2022.12.007_bib49","first-page":"769","article-title":"Guidelines for prevention and treatment of chronic hepatitis B","volume":"9","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.12.007_bib50","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.12.007_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104783","article-title":"Reasons to consider early treatment in chronic hepatitis B patients","volume":"177","author":"Koffas","year":"2020","journal-title":"Antivir Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822034596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822034596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:06Z","timestamp":1759175286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822034596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0168827822034596"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.12.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}